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Abstract  
The present study was to investigate whether/how the recombinant human cardiac IKs could 
be regulated by epidermal growth factor receptor kinase in HEK 293 cells stably expressing 
hKCNQ1/hKCNE1 genes using the approaches of perforated patch clamp technique and 
immunoprecipitation and Western blot analysis. It was found that the broad spectrum 
isoflavone tyrosine kinase inhibitor genistein and the selective epidermal growth factor 
receptor kinase inhibitor tyrphostin AG556 suppressed the recombinant IKs, and their 
inhibition was countered by the protein tyrosine phosphatase inhibitor orthovanadate. The 
Src-family kinase inhibitor PP2 reduced the current, but the effect was not antagonized by 
orthovanadate. Immunoprecipitation and Western blot analysis revealed that tyrosine 
phosphorylation level of hKCNQ1 protein was decreased by genistein or AG556, but not by 
PP2, These results provide the novel information that epidermal growth factor receptor kinase, 
but not Src-family kinases, regulates the recombinant cardiac IKs stably expressed in HEK 
293 cells via phosphorylating KCNQ1 protein of the channel. 
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1.  Introduction 
It is well known that protein tyrosine kinases regulate cell growth and differentiation [1], 
and also play an important role in the modulation of ion channels [2]. By the use of tyrosine 
kinase inhibitors (e.g. isoflavone genistein, tyrphostin compounds) and/or protein tyrosine 
phosphatase inhibitor (e.g. orthovanadate), several ionic channels/currents were found to be 
regulated by protein tyrosine kinases, including L-type Ca2+ current (ICa.L) in cardiac 
myocytes [3], smooth muscle cells [4], GH3 cells [5], volume sensitive chloride current 
(ICl.vol) in dog [6] and in human [7] cardiac myocytes, Na+ current (INa) in cardiac myocytes 
[8,9] and epithelial cells [10], and K+ currents in mouse Schwann cells [11], rat cardiac 
myocytes [12]. In addition, cloned KCNQ K+ channels expressed in CHO cells [13] and 
hERG channel stably expressed in HEK 293 cells [14] were also modulated by PTKs.  
 However, regulation of the slow delayed rectifier potassium current IKs by PTKs is not 
fully understood. In an earlier report, cell swelling-induced increase of cardiac IKs in dog 
ventricular myocytes was prevented by the broad-spectrum PTK inhibitor genistein, but not 
by its PTK-inactive analogue daidzein, suggesting that PTKs mediate the augmentation of IKs 
[15]. Nevertheless, in guinea pig ventricular myocytes, genistein was found to inhibit IKs in a 
PTK-independent pathway [16]. Recent reports demonstrated that cardiac IKs in guinea pig 
cardiac myocytes and in HEK 293 cells stably expressing KCNQ1/KCNE1 genes is 
suppressed by PTK inhibitors (e.g. genistein, tyrphostin compounds) in a PTK-dependent 
way [17, 18]. However, it is unclear whether the regulation of cardiac IKs is related to direct 
interaction with the channel protein or which specific PTK is involved. The present study 
employed the broad spectrum PTK inhibitor genistein, the Src-family kinase inhibitor PP2, 
the selective EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor tyrphostin 
AG556, and the protein tyrosine phosphatase inhibitor orthovanadate to determine which 
specific tyrosine kinase participates in the regulation of the recombinant cardiac IKs 
(hKCNQ1/hKCNE1) stably expressed in HEK 293 cells using perforated patch technique and 
immunoprecipitation and Western blot analysis. Our results demonstrated that EGFR tyrosine 
kinase, but not Src-family kinases, modulated the recombinant cardiac IKs via 
phosphorylating hKCNQ1 protein.  
 
 
 
2.  Materials and methods  
2.1.  Cell culture 
 The HEK 293 cell line stably expressing recombinant human cardiac KCNQ1/KCNE1 
channel (IKs) [19] was cultured in Dulbecco’s modified eagle medium (DMEM, Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum and 100 μg/ml hygromycin 
(Sigma-Aldrich, St Louis MO, USA). The cells were seeded on glass coverslips when used 
for electrophysiological recording. 
2.2.  Solutions and reagents 
 Tyrode solution contained (mM) NaCl 140, KCl 5.4, MgCl2 1.0, CaCl2 1.8, NaH2PO4 
0.33, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 10.0 and glucose 10 (pH 
was adjusted to 7.3 with NaOH). The pipette solution contained (mM) KCl 20, K-aspartate 
110, MgCl2 1.0, HEPES 10.0, pH was adjusted to 7.2 with KOH. The antibiotic amphotericin 
B (Sigma-Aldrich) was freshly added into the pipette solution (160-200 µg/ml) for perforated 
patch configuration [19].  
 3-(4-Chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP2) 
was purchased from Tocris (Bristol, UK). All other reagents were obtained from Sigma-
Aldrich. Stock solutions were made with dimethylsulfoxide (DMSO) for genistein (100 mM), 
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daidzein (100 mM), tyrphostin AG556 (AG 556) (100 mM), PP2 (20 mM). The stocks were 
divided into aliquots and stored at -20°C. Sodium orthovanadate stock solution (100 mM) 
was made with distilled water, and pH value was adjusted to 9.0. 
2.3.  Electrophysiology 
 Cells on a coverslip were transferred to an open cell chamber mounted on the stage of an 
inverted microscope and superfused with Tyrode solution at a rate of ~2 ml/min. Borosilicate 
glass electrodes (1.2-mm OD) were pulled with a Brown-Flaming puller (model P-97, Sutter 
Instrument, Novato, CA, USA) and had tip resistances of 1-2 MΩ when filled with the pipette 
solution. The currents were measured using an EPC-10 amplifier and Pulse software (Heka 
Elektronik, Lambrecht, Germany). A 3-M KCl–agar bridge was used as the reference 
electrode. The tip potential was zeroed before cell contact, the patch pipette solution 
contained 160-200 μg/ml amphotericin B to make perforated configuration. Access resistance 
gradually decreased, and became stable within 30 min. Only cells with constant series 
resistance (10–15 MΩ) were accepted for further study [19]. Electrical signals were low-pass 
filtered at 5 kHz and stored in the hard disk of an IBM compatible computer. All experiments 
were performed at room temperature (22-23 °C). 
2.4.  Immunoprecipitation and Western blot  
 The immunoprecipitation and Western blot analysis were performed as previously 
described [9, 14]. The HEK 293 cells stably expressing hKCNQ1/hKCNE1 genes were 
treated respectively with equivolume DMSO (control), 30 μM genistein, genistein plus 1 mM 
orthovanadate, 30 μM AG556, AG556 plus 1 mM orthovanadate, 1 mM orthovanadate, or 
cells with serum-free culture for 36 h, or the starved cells treated with 100 ng/ml EGF at 
room temperature. Following centrifugation at 4oC, the cell pellet was lysed with the lysis 
buffer containing (mM) 25 Tris, 150 NaCl, 100 NaF, 1.0 EDTA, 1.0 orthovanadate, 1.0 
phenylmethylsulfonyl fluoride, and 1% Na deoxycholate, 0.1% SDS, 1% Triton X-100, 1 
µg/ml leupeptin, and 1 µg/ml aprotinin. Protein quantification of lysates was made using a 
protein assay reader (Bio-Rad Laboratories, Hercules, CA), and diluted to equal 
concentrations. Proteins were immunoprecipitated overnight at 4°C using 2 μg of anti-
KCNQ1 antibody (sc-20816,  Santa Cruz Biotech, Santa Cruz, CA) and 100 µl of protein A 
beads (16-125, Millipore, Billerica, MA). Immunoprecipitated proteins bound to pelleted 
protein A beads were washed thoroughly in PBS, denatured in Laemmli sample buffer, 
separated using SDS-PAGE, and electroblotted onto nitrocellulose membranes. The 
immunoblots were probed with anti-pTyr-100 antibody (1:1000, Cat. 9411, Millipore, 
Billerica, MA) overnight at 4°C in a blocking solution containing 5% BSA in TBS and 
Tween 20, and subsequently treated with goat anti-mouse IgG-HRP antibody (1:5000, Santa 
Cruz Biotech, CA) for 1 h at room temperature. Blots were developed with enhanced 
chemiluminescence (ECL, Amersham Biosciences) and exposed on X-ray film (Fuji Photo 
Film GmbH). The blots were then stripped and reprobed with the anti-KCNQ1 antibody to 
determine total KCNQ1 protein. The film was scanned, imaged by a Bio-Imaging System 
(Syngene, Cambridge, UK), and analyzed via GeneTools software (Syngene) [14]. 
2.5.  Statistical analysis 
 Nonlinear curve-fitting was performed using Pulsefit (HEKA) and Sigmaplot (SPSS, 
Chicago, IL). Paired and/or unpaired Student’s t-test were used as appropriate to evaluate the 
statistical significance of differences between two group means, and analysis of variance was 
used for multiple groups. Group data are expressed as means ± SE. Values of P<0.05 were 
considered to be statistically significant. 
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3.  Results 
3.1.  Effect of genistein on IKs
It was reported that the broad spectrum PTK inhibitor genistein inhibited cardiac IKs in 
guinea pig cardiac myocytes [17,16]. We confirmed whether genistein would reduce the 
recombinant cardiac IKs stably expressed in HEK 293 cells.  Fig. 1A shows the time-course of 
the recombinant IKs recorded in a representative cell with a 3-s voltage step to +40 from −80 
mV, then back to −40 mV as shown in the inset in the absence and presence of 30 μM 
genistein. Genistein gradually inhibited IKs, and reached a steady-state effect within 8 min, 
and the effect recovered upon washout.  
Fig. 1B displays the voltage-dependent recombinant IKs traces recorded with 3-s voltage 
steps to between –60 and +60 from –80 mV (20-mV increments, 0.05 Hz), then back to –40 
mV as shown in the inset. Genistein reversibly inhibited the currents at all test potentials. 
Genistein at 30 μM reduced the IKs tail current (at test potential of +40 mV) to 8.3 ± 0.6 
pA/pF (n = 8, P<0.01 vs control) from 15.6 ± 1.3 pA/pF in control, and recovered to 14.6 ± 
1.2 pA/pF upon washout. Kinetics of the recombinant IKs was not affected by genistein (data 
not shown). Genistein inhibited the current in a concentration-dependent manner (Fig. 1C), 
and the current was reduced by 11.1±1.1, 25.7±1.6, 52.3±3.7, and 72.6±4.5% with 3, 10, 30, 
and 100 μM genistein, respectively.  These results indicate that genistein, as in native cardiac 
myocytes [17,16], inhibits the recombinant cardiac IKs expressed in HEK 293 cells.   
 In an earlier report, the observation of PTK-independent suppression of guinea pig 
cardiac IKs by genistein was based on that the PTK-inactive analogue daidzein produced a 
significant decrease of the current amplitude [16]. We also found that 100 μM daidzein 
induced a remarkable reduction of the recombinant IKs; however, 30 μM genistein produced a 
more pronounced suppression of the current in the same cell (Fig. 2A). The current inhibition 
(26.4±4.5%, n=6, P<0.01 vs control) with 100 μM daidzein was much weaker (Fig. 2A) than 
that (Fig. 1C, 52.5±3.7%, n=8) with 30 μM genistein (P<0.01 vs daidzein 100 μM).  
 The protein tyrosine phosphatase inhibitor orthovanadate was then employed to observe 
whether it would antagonize the genistein effect to determine whether the genistein effect on 
recombinant IKs is PTK-dependent. Orthovanadate (1 mM) exhibited a slight increase of the 
recombinant IKs (n=8, 5.5 ±3.1%, P<0.05), consistent with the previous report in guinea pig 
cardiac myocytes [17]. Fig. 2B displays the time course of the recombinant IKs in a typical 
experiment in the absence and presence of 30 μM genistein, and genistein plus 1 mM 
orthovanadate. Genistein remarkably suppressed the current amplitude, and the effect was 
countered by co-application of genistein and orthovanadate. Fig. 2C illustrates the mean 
percent values of the recombinant IKs with genistein, and genistein plus orthovanadate. 
Genistein (30 μM) reduced IKs.step to 49.2±3.1% of control, and the co-application of genistein 
with orthovanadate reversed the effect to 92.5±4.3% (n=6, P<0.01 vs genistein alone). These 
results suggest that the recombinant IKs inhibition by genistein is PTK-dependent.   
To investigate which specific PTK is involved in the regulation of the recombinant IKs, 
effects of the Src-related kinase inhibitor PP2 and the highly selective EGFR kinase inhibitor 
AG556 on the recombinant IKs and tyrosine phosphorylation level of hKCNQ1 protein are 
determined in the following experiments.  
3.2.  Effect of PP2 on IKs  
To determine whether Src-related PTKs would regulate the recombinant IKs, we tested 
the effect of the selective Src-family PTK inhibitor PP2 on the current amplitude. Fig. 3A 
shows the time course of the recombinant IKs recorded in a representative cell with the 
protocol shown in the inset in the presence of PP2.  PP2 at 1 μM, a concentration 200 times 
higher [20] than the EC50 of inhibiting Src-related kinases, had no effect on the current. 
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However, PP2 at 20 μM substantially decreased the current, but the effect could not be 
countered by 1 mM orthovanadate (Fig. 3B). The IKs.step was 610.5 ± 38.7 pA in control,  
488.4 ± 37.5 pA (n = 6, P<0.01 vs control) with 20 μM PP2, and 505 ± 40.4 pA (P=NS vs 
PP2 alone) with PP2 plus 1 mM orthovanadate. These results suggest that Src kinases may 
not be involved in the regulation of the recombinant IKs channel expressed in HEK 293 cells. 
3.3.  Effect of AG556 on IKs  
Fig. 4A shows the time course of the recombinant IKs recorded in a typical experiment 
with the voltage protocol shown in the inset in the absence and presence of 20 μM AG556 (a  
highly selective EGFR kinase inhibitor) [8,9,14], showed a remarkable suppression of the 
recombinant IKs. AG556 produced a significant inhibition of the recombinant IKs, and the 
effect recovered upon washout.  
 Fig. 4B displays the voltage-dependent IKs traces recorded in a representative cell with the 
voltage protocol shown in the inset. The IKs tail current at +40 mV was decreased to 10.4 ± 
0.8 pA/pF (n = 8, P<0.01 vs control) with 20 μM AG556 from 17.1 ± 1.4 pA/pF of control, 
and recovered to 15.1 ± 1.2 pA/pF upon washout. The concentration response relationship for 
the inhibition of the recombinant IKs by AG556 was evaluated at +40 mV (Fig. 4C). The 
IKs.step was reduced by 9.1 ± 0.5, 27.4 ± 1.8, 53.3 ± 2.1 and 67.2 ± 4.1% (P<0.05 or P<0.01) 
with 3, 10, 30 and 100 μM AG556, respectively. These results indicate that the selective 
EGFR kinase inhibitor AG556, like genistein, decreased the recombinant IKs.  
Fig. 5A shows that the tyrphostin PTK-inactive analogue tyrphostin 63 (A63, 100 μM) 
had no effect on the recombinant IKs, while AG556 (30 μM) produced a reversible inhibition 
of the current in a typical experiment. Similar results were obtained in seven other cells.  Fig. 
5B illustrates the time course of the recombinant IKs recorded in a representative cell. AG556 
at 30 μM induced a substantial decrease of the current, and the effect was fully countered by 
co-application of AG556 and 1 mM orthovanadate.  Fig. 5C summarizes the mean percent 
values of IKs.step (+40 mV) in the absence and presence of 30 μM AG556, and AG556 plus 1 
mM orthovanadate. The current was reduced to 56.5 ±5.8% of control with 30 μM AG556 
(P<0.01 vs control), and reversed to 95.6 ± 4.2% of control with co-application of AG556 
and 1 mM orthovanadate (P<0.01 vs AG556 alone). Orthovanadate significantly antagonized 
the inhibition of IKs by the selective EGFR kinase inhibitor AG556, suggesting that EGFR 
kinase participates in regulating the recombinant IKs. 
3.4.  Effect of EGF on IKs  
 To further determine the potential regulation of IKs by EGFR kinase, EGF (100 ng/ml) 
was directly applied in the bath solution. However, EGF was unable to enhance the 
recombinant IKs (n = 6, data not shown). To demonstrate whether it is related to the saturation 
of basal tyrosine phosphorylation of the channel, cells were cultured in a serum-free medium 
for 36 h. Fig. 6A shows the time course of the recombinant IKs (+40 mV) recorded in a 
representative cell with a 36-h starvation. The current was gradually increased by application 
of 100 ng/ml EGF. AG556 (20 μM) inhibited both EGF-induced current and basal current 
level.  Fig. 6B illustrates the mean percent values of IKs.step (+40 mV) in the absence and 
presence of 100 ng/ml EGF, and EGF plus 20 μM AG556. The current was increased to 
114.1 ± 5.6% of control (n=6, P<0.05 vs control) with EGF (100 ng/ml), and reduced to 75.3 
± 6.7% of control (P<0.01 vs EGF alone or control) with co-application of EGF and 20 μM 
AG556. These results indicate that basal tyrosine phosphorylation level of the recombinant 
IKs is saturated in cells with normal culture conditions (with 10% FBS) and EGF enhances the 
current only in starved cells.  
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3.5.  Tyrosine phosphorylation level of KCNQ1 
 The tyrosine phosphorylation level of KCNQ1 protein of IKs was determined with 
immunoprecipitation and Western blot analysis. Fig. 7A shows the images of tyrosine 
phosphorylation level of KCNQ1 with different treatments (30 min). Genistein (30 μM) and 
AG556 (30 μM) reduced the phosphorylation level of KCNQ1 protein and the reduction was 
substantially reversed by co-application of 1 mM orthovanadate. PP2 (20 μM) did not 
decrease the tyrosine phosphorylation level.  In addition, orthovanadate (1 mM) and EGF 
(100 ng/ml) had no effect on the tyrosine phosphorylation level of KCNQ1 in cells with 
normal culture conditions. The tyrosine phosphorylation level of KCNQ1 protein slightly 
reduced in cells with a serum-free culture for 36 h, and EGF countered the reduced 
phosphorylation level.  
 Fig. 7B summarizes the quantitative tyrosine phosphorylation levels of KCNQ1 protein. 
The tyrosine phosphorylation level of KCNQ1 protein was 72.8 ± 5.9% and 68.1%±6.7% of 
control with genistein and AG556, respectively (P<0.01 vs control). The phosphorylation 
level was 91.2 ± 7.7% and 93.6±7.9% of control respectively with genistein plus 
orthovanadate and AG556 plus orthovanadate (P<0.05 vs genistein alone or AG556 alone). 
PP2, orthovanadate, and EGF had no effect on the phosphorylation of KCNQ1 protein.  The 
serum-free starvation decreased the phosphorylation level to 90.1±8.7% (P>0.05 vs control), 
and the reduction was reversed by application of EGF. These results indicate that the 
reduction of tyrosine phosphorylation in KCNQ1 protein caused by EGFR kinase inhibition 
can be countered by inhibiting protein tyrosine phophatases. Basal KCNQ1 tyrosine 
phosphorylation is saturated; therefore, additional stimulation would not increase the 
phosphorylation level with EGF or orthovanadate, and a 36-h serum-free starvation induces a 
slight reduction of the phosphorylation in HEK 293 cells stably expressing 
hKCNQ1/hKCNE1 genes.     
 
4.  Discussion  
 The slowly delayed rectifier IKs is an important repolarizing current in mammalian hearts 
[21,22]. It has been demonstrated that serine/threonine protein kinases (e.g. PKA and PKC) 
regulate IKs [23,24]. Activation of PKA by cAMP increases IKs density and produces a rate-
dependent shortening of action potential duration, which underlies the sympathetic nervous 
system regulation of cardiac function mediated by β-adrenergic receptor activation, and 
pharmacological therapeutics [25]. In addition, cardiac IKs or recombinant IKs was regulated 
by  phospholipid phosphatidylinositol-4,5-bisphosphate (PIP2) [26,27,28] and calmodulin 
[29]. Previous reports [15,17,30] and the present observation provide additional information 
that cardiac IKs is regulated by PTKs.    
 The earliest evidence of IKs regulation by PTKs was reported by Zhou and colleagues in 
dog ventricular myocytes, in which swelling-induced increase of IKs was counted by the PTK 
inhibitor genistein, but not by its PTK-inactive analogue daidzein [15]. However, the later 
study from Washizuka and co-workers showed a PTK-independent suppression of cardiac IKs 
by genistein based on the observation that the PTK-inactive analog daidzein also significantly 
decreased the current amplitude [16]. A recent study from Missan and colleagues confirmed 
that the genistein-induced reduction of IKs was PTK-dependent, because the current inhibition 
was remarkably antagonized by the protein tyrosine phosphatase inhibitor orthovanadate [17]. 
In addition, orthovanadate also countered the IKs suppression by the  inhibitor tyrphostin A23 
or A25 in guinea pig cardiac myocytes [17].  
 In the present study, we also employed pharmacological tools of PTK inhibitors, in which 
the selectivity is relative [2] and nonselective effect is reported previously [16], to determine 
the regulation of recombinant IKs by PTKs; however, the result with a wide range of 
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concentrations (3-100 μM) of the broad spectrum PTK inhibitor genistein supports the notion 
that the suppression of IKs by this inhibitor is PTK-dependent, since the current inhibition by 
the selected concentration (30 μM) of genistein was not only greater than that by 100 
daidzein (a PTK-inactive analogue), but also antagonized by the protein tyrosine phosphatase 
inhibitor orthovanadate (Fig. 2). The further experiments demonstrated that the inhibition of 
IKs by the selective EGFR kinase inhibitor AG556 (30 μM), but not the Src-family kinase 
inhibitor PP2 (20 μM), was almost fully countered by orthovanadate (Fig. 5). Therefore, the 
reduction of IKs by 20 μM PP2 is likely mediated by PTK-independent inhibition, while the 
AG556 suppression of the current is mediated by EGFR kinase inhibition. Thus, the new 
finding of the present study is that EGFR kinase, but not Src-related kinases, participates in 
the regulation of recombinant IKs. The immunoprecipitation and Western blot analysis further 
revealed that PP2 had no effect on tyrosine phosphorylation level of KCNQ1 protein, 
whereas genistein and AG556 remarkably decreased the tyrosine phosphorylation level, and 
the reduced phosphorylation level was reversed by orthovanadate (Fig. 7). These results 
suggest that EGFR kinase, but not Src-related kinases, regulates IKs activity by 
phosphorylating α-subunit KCNQ1 protein of the channel.   
 It has been demonstrated that endogenous EGFRs are present in HEK 293 cells [31]. Our 
previous study demonstrated both EGFR kinase and Src-related kinases regulate the α-
subunit hERG current of human cardiac IKr [14]; however, it is not the case for the 
recombinant cardiac IKs, because the inhibition of the recombinant IKs by PP2 could not be 
countered by the protein tyrosine phosphatase inhibitor orthovanadate (Fig. 3) and tyrosine 
phosphorylation level of KCNQ1 protein is not reduced by PP2 (Fig. 7). Our results are 
supported by the previous report in which KCNQ1 channel expressed in CHO cells is not 
modulated by Src-family kinases [32].   
 The present observation and previous studies [17, 30, 15] have demonstrated that there is 
no doubt that cardiac IKs is regulated by PTKs. However, the recent study from Missan and 
colleagues did not demonstrate the evidence that IKs channels are directly phosphorylated by 
PTKs based on the results that cells co-expressed KCNE1 with KCNQ1 mutants at Y51, 
Y111, Y171, Y184, Y395, Y461, Y662 with phenylalanine did not show a remarkable 
reduction of the channel inhibition by the PTK inhibitor A25 (compared to that of wild type 
KCNQ1) [18]. However, they did find that four mutants (at Y51, Y94, Y111 and Y382) of 
KCNQ1 showed a trend to decrease the current inhibition by the PTK inhibitor A25, though 
the reduction was not statistically significant [18], which is most likely that more than one 
tyrosine of the channel is involved in the phosphorylation.   
 In the present study, the immunoprecipitation and Western blot analysis provide a strong 
evidence of KCNQ1 tyrosine phosphorylation of the recombinant IKs. The phosphorylation 
level was decreased by genistein or AG556, and the reduction of the phosphorylation was 
countered by the protein tyrosine phosphatase inhibitor orthovanadate (Fig. 7), indicating a 
direct evidence that IKs is regulated by EGFR kinase.  
Our patch clamp results showed that the recombinant IKs was enhanced by EGF only in 
the starved cells cultured with a serum-free medium for a 36-h (Fig. 6), but not in cells 
cultured with  a normal medium (containing 10% serum). The biochemical experiments also 
showed that tyrosine phosphorylation level of the recombinant KCNQ1 was not enhanced by 
EGF or orthovanadate in cells cultured with a normal medium; however, the tyrosine 
phosphorylation level was reduced in the cells cultured with serum-free medium for a 36-h, 
even the reduction was not statistically significance. This suggests the basal tyrosine 
phosphorylation of KCNQ1 subunit in HEK 293 cells is saturated, and therefore is highly 
sensitive to the inhibition of EGFR kinase (Fig. 7).  
   It is well known that IKs plays an important role in cardiac repolarization [21,22]. In 
addition to the regulation by protein kinases PKA and PKC [23,24], cardiac IKs is modulated 
 
BBAMEM-09-417R1 
8
by PIP2 [33,26,27,28] and calmodulin [29]. Dysfunction of IKs, resulting from either the gene 
mutations or cardiac diseases such as chronic heart failure, can induce inherited or acquired 
long-QT syndromes which are often associated with life-threatening arrhythmias in emotional 
or physical stress [34,35,36,37], which is also related to abnormal phosphorylation of the IKs 
channel proteins [38]. Previous studies and the present observation provide the strong 
evidence that cardiac IKs could also be modulated by interaction with protein tyrosine 
phosphatases and EGFR tyrosine kinase. However, whether and how the alteration of IKs 
channel regulation by protein tyrosine phosphatases and/or EGFR tyrosine kinase participates 
in the pathophysiological and electrical remodeling in cardiac disorders remains to be studied.  
Collectively, the present study has demonstrated the novel information that the 
recombinant human cardiac IKs stably expressed in HEK 293 cells is regulated by EGFR 
tyrosine kinase, but not by Src-family kinases. 
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Fig. 1. Effect of genistein on the recombinant IKs. A. Time-course of the recombinant IKs 
recorded in a typical experiment with 3-s voltage step to +40 from –80 mV, then back to –40 
mV (to recorded IKs tail current) as shown in the inset in the absence and presence of 30 μM 
genistein. Original IKs traces at corresponding time points are shown in right of the panel. B. 
Voltage-dependent IKs traces recorded in a representative cell with 3-s voltage steps to 
between –60 and +60 mV from –80 mV (20-mV increment, 0.05 Hz), then to –40 mV (inset) 
in the absence and presence of 30 μM genistein. Genistein reversibly inhibited the voltage-
dependent current. C. Mean percent value of the recombinant IKs (at +40 mV) inhibition by 3, 
10, 30 and 100 μM genistein. The number in the parenthesis indicates the experimental 
number. *P<0.05; **P<0.01 vs control. 
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Fig. 2. Orthovanadate on genistein effect.  A. Time-course of the recombinant IKs recorded 
in a typical experiment in the absence and presence of 100 μM daidzein or 30 μM genistein. 
Original current traces at corresponding time points are shown in right of the panel.  B. Time-
course of the recombinant IKs recorded in a representative cell in the absence and presence of 
30 μM genistein and genistein plus 1 mM orthovanadate (OV). Original current traces at 
corresponding time points are shown in right of the panel. C. Histogram shows the mean 
percent values of IKs.step during control, in the presence of 30 μM genistein, and genistein plus 
1 mM orthovanadate. n= 8, **P<0.01 vs control; #P<0.01 vs genistein alone. 
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Fig. 3. PP2 effect on the recombinant IKs.  A. Time-course of the recombinant IKs recorded 
in  a representative cell with the protocol shown in the inset during control, in the presence of 
1 μM PP2. Original current traces at corresponding time points are shown in right of the panel.  
B. Time-course of the recombinant IKs recorded in a typical experiment in the presence of 20 
μM PP2, and PP2 plus 1 mM orthovanadate (OV). Original current traces at corresponding 
time points are shown in right of the panel. 
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Fig. 4. Effect of AG556 on the recombinant IKs. A. Time-course of IKs recorded in a 
representative cell in the absence and presence of 20 μM AG556 with the protocol shown in 
the inset. Original IKs traces are shown in right of the panel. B. Voltage-dependent IKs traces 
recorded in a representative cell with the voltage protocol as shown in the inset in the absence 
and presence of 20 μM AG556. C. Mean percent value of the recombinant IKs (at +40 mV) 
inhibition by 3, 10, 30 and 100 μM AG556. The number in the parenthesis indicates the 
experimental number. *P<0.05; **P<0.01 vs control. 
 
BBAMEM-09-417R1 
15
 
 
 
Fig. 5. Orthovanadate on AG556 effect.  A. Time-course of IKs recorded from a 
representative cell with the voltage protocol as shown in the inset in the absence and presence 
of 100 μM tyrphostin 63 (A63) or 30 μM AG556. Original current traces at corresponding 
time points are shown in right of the panel. B. Time-course of IKs recorded in typical 
experiment in the absence and presence of 30 μM AG556 and AG556 plus 1 mM 
orthovanadate (OV). Original current traces at corresponding time points are shown in right of 
the panel. C. Histogram shows the mean percent values of the recombinant IKs (at +40 mV) 
during control, in the presence of 30 μM AG556 and after  co-application of AG556 and 1 
mM orthovanadate. n=7, **P<0.01 vs control; #P<0.01 vs AG556 plus orthovanadate. 
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Fig. 6. EGF enhanced the recombinant IKs in cells with serum-free culture.  A. Time-
course of IKs recorded in typical experiment in the absence and presence of 100 ng/ml EGF 
and after co-application of EGF and 20 μM AG556. Original current traces at corresponding 
time points are shown in right of the panel.  B. Histogram showing the mean percent values of 
the recombinant IKs (at +40 mV) in cells with a 36-h serum-free culture during control, in the 
presence of 100 ng/ml EGF and after co-application of EGF and 20 μM AG556. n = 6, 
*P<0.05, **P<0.01 vs control; # P<0.01 vs EGF alone. 
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Fig. 7. Tyrosine phosphorylation level of recombinant IKs. A. Upper panel, protein lysates 
were immunoprecipitated with anti-KCNQ1 antibody, Western blots were then prepared and 
probed with the anti-phosphotyrosine (Tyr(P)) antibody. Lower panel, Western blots of cell 
lysates, probed with the anti-KCNQ1 antibody. B. Histogram summarizes the mean values of 
the relative levels of tyrosine-phosphorylated KCNQ1 protein analyzed by the densitometry. 
The density of the immunoprecipitation (as in A) was normalized to that of the Western blots. 
Relative phosphorylated protein level (n=4 experiments) is expressed as a percentage of the 
vehicle control.  **P<0.01 vs vehicle control, #P<0.05 vs genistein or AG556 alone. 
 
 
 
 
 
 
